Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:OREXQ NASDAQ:TRVN NASDAQ:VINC NASDAQ:WINT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOREXQOrexigen Therapeutics$0.01+35.9%$0.01$0.00▼$0.16$100K4.9880,439 shs60,300 shsTRVNTrevena$0.25+20,733.3%$0.68$0.00▼$7.85$240K0.412,161 shs6,905 shsVINCVincerx Pharma$0.03-24.9%$0.04$0.03▼$17.00$170K1.71556,253 shs145,819 shsWINTWindtree Therapeutics$0.10-0.9%$0.60$0.09▼$487.50$348K0.635.76 million shs233,507 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOREXQOrexigen Therapeutics0.00%0.00%0.00%0.00%0.00%TRVNTrevena0.00%-9.09%-72.53%-78.26%-94.08%VINCVincerx Pharma0.00%-17.51%-18.14%-32.99%-99.79%WINTWindtree Therapeutics0.00%-26.85%-85.91%-87.86%-99.98%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATRVNTrevena0.8973 of 5 stars3.02.00.00.00.00.00.6VINCVincerx Pharma2.4699 of 5 stars3.53.00.00.00.61.71.3WINTWindtree Therapeutics2.2861 of 5 stars3.04.00.00.02.00.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOREXQOrexigen Therapeutics 0.00N/AN/AN/ATRVNTrevena 2.00Hold$5.001,900.00% UpsideVINCVincerx Pharma 3.00Buy$40.00122,976.92% UpsideWINTWindtree Therapeutics 2.00Hold$350.00367,933.65% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOREXQOrexigen Therapeutics$33.71M0.00N/AN/AN/A∞TRVNTrevena$443K0.54N/AN/A($11.07) per share-0.02VINCVincerx PharmaN/AN/AN/AN/A$10.50 per shareN/AWINTWindtree TherapeuticsN/AN/AN/AN/A$0.98 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOREXQOrexigen Therapeutics-$24.52MN/A0.00∞N/AN/AN/AN/AN/ATRVNTrevena-$40.29M-$47.04N/AN/AN/AN/AN/A-119.55%11/5/2025 (Estimated)VINCVincerx Pharma-$40.16M-$20.60N/AN/AN/AN/A-248.33%-132.73%9/4/2025 (Estimated)WINTWindtree Therapeutics-$1.79M-$823.47N/AN/AN/AN/A-207.34%-50.19%N/ALatest OREXQ, WINT, VINC, and TRVN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025WINTWindtree Therapeutics-$99.00-$3.06+$95.94-$3.06$3.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOREXQOrexigen TherapeuticsN/AN/AN/AN/AN/ATRVNTrevenaN/AN/AN/AN/AN/AVINCVincerx PharmaN/AN/AN/AN/AN/AWINTWindtree TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOREXQOrexigen TherapeuticsN/AN/AN/ATRVNTrevenaN/A2.422.42VINCVincerx PharmaN/A2.172.17WINTWindtree TherapeuticsN/A0.430.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOREXQOrexigen TherapeuticsN/ATRVNTrevena13.56%VINCVincerx Pharma44.02%WINTWindtree Therapeutics29.33%Insider OwnershipCompanyInsider OwnershipOREXQOrexigen Therapeutics13.30%TRVNTrevena2.70%VINCVincerx Pharma15.60%WINTWindtree Therapeutics0.15%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOREXQOrexigen Therapeutics13218.89 millionN/ANot OptionableTRVNTrevena40959,000841,000OptionableVINCVincerx Pharma605.23 million1.89 millionNot OptionableWINTWindtree Therapeutics303.66 million3.66 millionNot OptionableOREXQ, WINT, VINC, and TRVN HeadlinesRecent News About These CompaniesWarrington’s Windtree Therapeutics Faces Uncertain Future After NASDAQ DelistingAugust 27, 2025 | msn.comBNB Treasury Firm Windtree Therapeutics Plunges 77% After Nasdaq Delisting NoticeAugust 22, 2025 | thecurrencyanalytics.comTBNB treasury company plunges 77% after Nasdaq delisting noticeAugust 22, 2025 | cointelegraph.comBNB hits new all-time high even as treasury company Windtree Therapeutics faces Nasdaq delistingAugust 20, 2025 | fxstreet.comNasdaq to Delist BNB Treasury Firm Windtree Therapeutics, Stock Crashes 76%August 20, 2025 | coingape.comCWindtree Therapeutics Faces Nasdaq Delisting NoticeAugust 20, 2025 | msn.comWindtree Therapeutics Delays Q2 2025 Report FilingAugust 14, 2025 | tipranks.comWindtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025August 11, 2025 | globenewswire.comWindtree Therapeutics Terminates SEISMiC-C Clinical StudyAugust 11, 2025 | theglobeandmail.comWindtree Advances Istaroxime Toward Global Phase 3 Following Positive Interim Study ResultsAugust 7, 2025 | msn.comWindtree Announces Istaroxime Phase 2 Interim Analysis in SCAI Stage C Cardiogenic Shock PatientsAugust 5, 2025 | taiwannews.com.twTWindtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy RolloutJuly 30, 2025 | msn.comWindtree Therapeutics Announces Large Reduction of Preferred Series C and D Shares Outstanding by Conversion and RedemptionJuly 29, 2025 | globenewswire.comWindtree Therapeutics Bets $520M on Binance Coin in Unprecedented Crypto PivotJuly 26, 2025 | thecurrencyanalytics.comTWindtree Therapeutics Commits Up to $700 Million to Build BNB Treasury Following All-Time HighJuly 26, 2025 | techstory.inTWindtree Therapeutics Secures $520 Million in Equity Agreements to Expand BNB Cryptocurrency HoldingsJuly 26, 2025 | msn.comWindtree Therapeutics Targets $520 Million in Funding to Secure BNB ReserveJuly 25, 2025 | beincrypto.comBNasdaq-listed Windtree Therapeutics Commits $520M to BNB in Bold Treasury PivotJuly 25, 2025 | blockonomi.comWindtree Therapeutics Taps $520M to Build BNB Reserves — Is Pharma Going Crypto?July 25, 2025 | crypto-news-flash.comCWindtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury StrategyJuly 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOREXQ, WINT, VINC, and TRVN Company DescriptionsOrexigen Therapeutics OTCMKTS:OREXQ$0.0053 +0.00 (+35.90%) As of 05/31/2019Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.Trevena NASDAQ:TRVN$0.25 +0.25 (+20,733.33%) As of 08/29/2025 02:24 PM EasternTrevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Vincerx Pharma NASDAQ:VINC$0.03 -0.01 (-24.94%) As of 08/29/2025 03:26 PM EasternVincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.Windtree Therapeutics NASDAQ:WINT$0.10 0.00 (-0.94%) As of 08/29/2025 03:52 PM EasternWindtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
